Friday, Nov 20, 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
59.49
1.15
+1.97%
Follow BMY
Alert me
Q3 2026 quarterly report Bristol Myers Squibb cut its full-year earnings guidance, one of four health-care companies to do so as government funding and drug pricing changed. Read it in the report
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 19,427 | 20,776 | 22,561 | 26,145 | 42,518 | 46,385 | 46,159 | 45,006 | 48,300 | 48,194 | 50,033 | +10.6% | 50,234 | 48,801 | 40,543 | (5.6%) | |
| Gross margin, % | 74.42 | 71.05 | 71.34 | 69.10 | 72.31 | 78.57 | 78.04 | 76.24 | 71.08 | 71.08 | 69.24 | (3.3) pt | ||||||
| EBT | 5,915 | 5,131 | 5,968 | 4,975 | (6,871) | 8,098 | 7,713 | 8,440 | (8,379) | 9,328 | 11,332 | +5.2% | ||||||
| EBT margin, % | 30.45 | 24.70 | 26.45 | 19.03 | (16.16) | 17.46 | 16.71 | 18.75 | (17.35) | 19.36 | 22.65 | (11.1) pt | ||||||
| Net income | 4,507 | 975 | 4,947 | 3,460 | (8,995) | 7,014 | 6,345 | 8,040 | (8,933) | 7,055 | 9,241 | +5.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 11.63 | 12.63 | 13.82 | 15.33 | 18.83 | 20.88 | 21.67 | 21.75 | 23.83 | 23.69 | 24.49 | +8.2% | |||||
| Earnings | 2.67 | 0.61 | 3.03 | 2.02 | (3.99) | 3.15 | 2.97 | 3.88 | (4.41) | 3.47 | 4.52 | +3.0% | ||||||
| Cash flow | 1.83 | 3.21 | 4.33 | 4.82 | 6.22 | 7.30 | 6.13 | 6.70 | 7.49 | 6.96 | 5.21 | +16.0% | ||||||
| Capex | (0.73) | (0.64) | (0.58) | (0.49) | (0.33) | (0.44) | (0.52) | (0.58) | (0.62) | (0.64) | (0.67) | (1.3%) | ||||||
| Free cash flow | 1.10 | 2.57 | 3.74 | 4.32 | 5.89 | 6.86 | 5.61 | 6.11 | 6.88 | 6.32 | 4.55 | +21.4% | ||||||
| Book value | 9.78 | 7.20 | 8.65 | 30.32 | 16.78 | 16.21 | 14.61 | 14.25 | 8.08 | 9.10 | 11.46 | (0.8%) | ||||||
| Shares, m | 1,671 | 1,645 | 1,633 | 1,705 | 2,258 | 2,221 | 2,130 | 2,069 | 2,027 | 2,034 | 2,039 | +2.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 22.27 | 100.51 | 17.16 | 29.05 | 0.00 | 19.79 | 24.25 | 13.60 | 0.00 | 15.59 | 12.91 | 24.2 | |||||
| P/S | 5.11 | 4.85 | 3.76 | 4.19 | 3.29 | 2.99 | 3.33 | 2.43 | 2.37 | 2.28 | 2.38 | 3.5 | ||||||
| P/B | 6.08 | 8.51 | 6.01 | 2.12 | 3.70 | 3.85 | 4.95 | 3.70 | 7.00 | 5.93 | 5.09 | 5.2 | ||||||
| EV/Sales | 5.13 | 4.91 | 3.70 | 5.38 | 4.11 | 3.58 | 3.99 | 3.04 | 3.18 | 2.99 | 2.99 | 4.0 | ||||||
| EV/FCF | 54.10 | 24.17 | 13.65 | 19.09 | 13.15 | 10.90 | 15.40 | 10.80 | 11.01 | 11.22 | 16.10 | 18.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 3,058 | 5,275 | 7,066 | 8,210 | 14,052 | 16,207 | 13,066 | 13,860 | 15,190 | 14,156 | 10,652 | +18.6% | |||||
| Capex | (1,215) | (1,055) | (951) | (836) | (753) | (973) | (1,118) | (1,209) | (1,248) | (1,311) | (1,366) | +0.8% | ||||||
| Free cash flow | 1,843 | 4,220 | 6,115 | 7,374 | 13,299 | 15,234 | 11,948 | 12,651 | 13,942 | 12,845 | 9,286 | +24.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 4,863 | 5,291 | 7,062 | 11,050 | 11,112 | 11,394 | 5,383 | 9,508 | 6,006 | 5,973 | 11,014 | +2.3% | |||||
| Net debt | 358 | 1,150 | (1,410) | 31,340 | 34,845 | 27,587 | 30,067 | 27,492 | 38,790 | 34,438 | 30,296 | +66.1% | ||||||
| Shareholders’ equity | 16,347 | 11,847 | 14,127 | 51,698 | 37,882 | 36,006 | 31,118 | 29,485 | 16,388 | 18,506 | 23,404 | +1.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 13.62 | 2.99 | 14.36 | 4.17 | (7.26) | 6.14 | 6.14 | 8.36 | (9.53) | 7.72 | 9.96 | (5.9) pt | |||||
| ROIC | 22.13 | 24.67 | 29.33 | 3.74 | (5.90) | 7.96 | 7.88 | 9.26 | (9.49) | 11.01 | 13.19 | (11.1) pt | ||||||
| ROE | 28.97 | 7.14 | 37.88 | 10.45 | (20.13) | 18.93 | 18.85 | 26.48 | (39.01) | 40.43 | 44.01 | +11.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 25,000 | 23,700 | 23,300 | 30,000 | 30,250 | 32,200 | 34,300 | 34,100 | 34,100 | 32,500 | — | +3.0% | |||||
| Revenue/emp, $m | 0.78 | 0.88 | 0.97 | 0.87 | 1.41 | 1.44 | 1.35 | 1.32 | 1.42 | 1.48 | — | +7.4% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Business profile
Where the money comes from and where it goes Fiscal 2025
| United States | 33,279 | 69.05% |
|---|---|---|
| International | 13,828 | 28.69% |
| Other | 1,087 | 2.26% |
| Gross margin | 71.08% | |
| Operating margin | 19.36% | |
| Pre-tax margin | 19.36% |
Bristol Myers Squibb Company vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | Compare |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | Compare |
| NVO Novo Nordisk A/S | $128.6B | 9.8× | — | +3.87% (above 0%: growing) | −17.14% (below 0%: shrinking) | −14.75% (below 0%: shrinking) | 76.97% | 29.06% | Compare |
| BMY Bristol Myers Squibb Company | $119.3B | 12.9× | 12.0× FY26e | +6.93% (above 0%: growing) | −2.78% (below 0%: shrinking) | −35.95% (below 0%: shrinking) | 68.28% | 19.40% | |
| SNY Sanofi | $111.3B | 22.8× | — | +13.89% (above 0%: growing) | +8.21% (above 0%: growing) | +99.60% (above 0%: growing) | 76.16% | 28.53% | Compare |
| GSK GSK PLC Sponsored ADR | $95.9B | 16.4× | 15.5× FY26e | +3.75% (above 0%: growing) | −23.88% (below 0%: shrinking) | +62.44% (above 0%: growing) | 73.11% | 23.93% | Compare |
| Median of peers | $183.0B | 24.6× | 24.0× | +5.69% | −13.41% | +11.01% | 76.08% | 27.80% |
From the latest earnings call
- Chief Financial Officer David Elkins said growth in Eliquis more than offset generic-driven declines elsewhere in the legacy portfolio, while the growth portfolio expanded.
- Elkins expects Eliquis revenue to step down in 2027 and said Bristol Myers Squibb is on track to achieve productivity efficiencies by year-end.
Largest institutional holders 13F, quarter to Jun 30, 2026
Held by institutions
81.67%
Held by the ten largest
39.91%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| Vanguard | 202.27m | 9.90% | +2.11m |
| BlackRock | 180.38m | 8.83% | +8.70m |
| State Street | 102.41m | 5.01% | +3.84m |
| JPMorgan Chase | 71.71m | 3.51% | −20.76m |
| Charles Schwab | 67.60m | 3.31% | +6.48m |
| Geode Capital Management | 56.44m | 2.76% | +1.16m |
| Norges Bank | 36.87m | 1.80% | +36.87m |
| Bank of America | 34.05m | 1.67% | +1.46m |
| T. Rowe Price | 31.73m | 1.55% | +21.46m |
| UBS | 31.72m | 1.55% | +1.80m |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
Pay and ownership Proxy statement filed Mar 25, 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 21.88m | 16.86m | 105.00 |
| 2024 | 18.79m | 21.20m | 105.00 |
| 2022 | 20.05m | 35.06m | 123.00 |
| 2021 | 19.78m | 16.51m | 103.00 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement
Bristol Myers Squibb Company (BMY) Latest News
What happened
- Results Bristol Myers Squibb raised its 2026 revenue outlook as its growth portfolio sales rose 12% to about $7.7 billion.
- Other Bristol Myers Squibb reported preliminary open-label Phase 3 findings showing symptom improvements with KarXT in Alzheimer’s-related psychosis.
- Leadership Bristol Myers Squibb combined its research and development teams under Cristian Massacesi, effective January 1, 2027.
- Other Bristol Myers Squibb reported sustained efficacy and no new safety signals in 56-week Phase 3 data for pediatric Camzyos patients.
- Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Rally Already Priced In? Simply Wall St.
- What Could Derail Bristol Myers Squibb Stock? Trefis
- Bristol Myers Squibb Q3 Earnings Call Highlights MarketBeat
- Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction The Motley Fool
- Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians TIKR
- Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript The Motley Fool transcript
- BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook Zacks
- Bristol Myers Squibb Reports 7% Rise in Q3 Revenue to $13.07 Billion and Raises 2026 Sales Outlook InvestorsHub earnings
- Bristol Myers: Q3 Earnings Snapshot Associated Press
- Should You Buy Bristol Myers Squibb Stock For Its Cash? Trefis
16 more headlines
- Which Dates Could Move Bristol Myers Squibb Stock Most? Trefis
- Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027? 24/7 Wall St. +1 report
- BMY Q3 deep dive: pipeline advances offset margin pressure as guidance shifts StockStory
- BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock? Zacks
- Bristol Myers Squibb Stock: Is Wall Street Bullish or Bearish? Barchart
- What Bristol Myers Squibb Stock's Earnings Beat Means For Shareholders Simply Wall St.
- BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress Zacks
- What Exelixis (EXEL) Said on Its Q3 Earnings Call MarketBeat
- Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings Zacks
- Bristol-Myers Squibb’s (NYSE:BMY) Q3 2026 sales top estimates StockStory
- Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates Zacks
- Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 Business Wire
- Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy? Zacks
- How Much Should One Number Worry Merck Stock Holders? Trefis
- Why Should Pfizer Stock Holders Watch This One Number? Trefis
- Bristol-Myers Squibb (BMY) Q3 earnings: what to expect StockStory
BMY metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, licenses, manufactures and sells prescription medicines for serious diseases. Its work spans cancer, blood disorders, immune diseases, cardiovascular conditions and neuroscience. It sells medicines worldwide, mainly through wholesalers, distributors and specialty pharmacies, while promoting their approved uses to healthcare professionals.
Its products include Opdivo, a cancer medicine used in several tumor types, and Eliquis, an oral medicine used to reduce stroke risk in certain patients and to treat blood clots. Camzyos treats adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart condition; Cobenfy treats schizophrenia in adults. Breyanzi is a cell therapy for certain blood cancers.